In case you missed it: June 27 to July 1

"Despite advances in SCD management and high-risk pregnancy care, at the national level, outcomes in this population have not improved since the last NIS analysis of data from 1999 to 2008," investigators write.

This is part 2 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.

Trust the trends you can see and make investments in your practice to move forward.

This is part 1 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.

The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.

The rare condition can lead to life-threatening anemia in the fetus and currently lacks FDA-approved treatments.